EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cystic fibrosis: Correction of a fatal disease

Jeffrey M Friedman iD

Proceedings of the National Academy of Sciences · 16.09.2025 · 122 (37)

DOI: 10.1073/pnas.2519780122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 11.09.2025. Verfasst von Jeffrey M Friedman. Beteiligte Einrichtung: HHMI at Rockefeller University, New York, NY 10065. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 2025 Lasker~DeBakey Clinical Medical Research Award has been given to Michael Welsh, Jesús (Tito) González, and Paul Negulescu for their key roles in developing a novel treatment for cystic fibrosis (CF)—a three-drug combination that saves the lives of people with this lethal genetic disease [D. Keating et al. , N. Engl. J. Med. 379, 1612–1620 (2018)]. The disease is caused by mutations that disrupt the function of a gene known as CF Transmembrane Conductance Regulator which encodes a chloride channel expressed in epithelial cells including the lung. Collectively the three recipients were responsible for the development of novel high-throughput drug screens that led to the development of the new drugs. Welsh is a pulmonologist who played a key role in understanding the physiology and pathophysiology of the disease. González is a physical organic chemist who developed a novel technology that enabled robust high-throughput screens for drugs that correct the channel defects. Negulescu led a group of extremely talented biologists, chemists, and physicians who built on these advances to develop novel three-drug combinations that have miraculous benefits for the majority of afflicted patients. This advance represents a true milestone in medicine and fulfills a dream of research scientists and families—the conversion of a fatal disease into a fully treatable one. It is also a stunning example of the power of medical research to save people’s lives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansCystic Fibrosis Transmembrane Conductance RegulatorMutationAnimals

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorCFTR protein, human

Autor:innen und Institutionen

  • HHMI at Rockefeller University, New York, NY 10065.

ORCID-Profile: Jeffrey M Friedman

Zitieren

APA

Friedman, J. M. (2025). Cystic fibrosis: Correction of a fatal disease. Proceedings of the National Academy of Sciences, 122(37). https://doi.org/10.1073/pnas.2519780122

Vancouver

Friedman JM. Cystic fibrosis: Correction of a fatal disease. Proceedings of the National Academy of Sciences. 2025;122(37). doi:10.1073/pnas.2519780122

BibTeX
@article{Friedman2025,
  author = {Friedman, Jeffrey M},
  title = {Cystic fibrosis: Correction of a fatal disease},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {37},
  doi = {10.1073/pnas.2519780122}
}
Kostenlos starten →